KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Asset Writedowns and Impairment: 2016-2024

Historic Asset Writedowns and Impairment for Elanco Animal Health (ELAN) over the last 9 years, with Dec 2024 value amounting to $81.0 million.

  • Elanco Animal Health's Asset Writedowns and Impairment rose 60.00% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year decrease of 33.02%. This contributed to the annual value of $81.0 million for FY2024, which is 153.12% up from last year.
  • According to the latest figures from FY2024, Elanco Animal Health's Asset Writedowns and Impairment is $81.0 million, which was up 153.12% from $32.0 million recorded in FY2023.
  • Over the past 5 years, Elanco Animal Health's Asset Writedowns and Impairment peaked at $345.0 million during FY2021, and registered a low of $25.0 million during FY2020.
  • Its 3-year average for Asset Writedowns and Impairment is $64.7 million, with a median of $81.0 million in 2022.
  • In the last 5 years, Elanco Animal Health's Asset Writedowns and Impairment skyrocketed by 1,280.00% in 2021 and then crashed by 76.52% in 2022.
  • Elanco Animal Health's Asset Writedowns and Impairment (MRY) stood at $25.0 million in 2020, then soared by 1,280.00% to $345.0 million in 2021, then plummeted by 76.52% to $81.0 million in 2022, then plummeted by 60.49% to $32.0 million in 2023, then soared by 153.12% to $81.0 million in 2024.
  • Its Asset Writedowns and Impairment stands at $81.0 million for FY2024, versus $32.0 million for FY2023 and $81.0 million for FY2022.